Carfilzomib

Generic Name: Carfilzomib

Brand Names: Kyprolis

Drug Type: Small Molecule

Chemical Formula: C_₄₀H_₅₇N_₅O_₇

CAS Number: 868540-17-4

Unique Ingredient Identifier: 72X6E3J5AR

Background: Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.

Indication: Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

Associated Conditions: Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical Trials

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 2

Terminated

Conditions: Refractory Plasma Cell Myeloma
Recurrent Plasma Cell Myeloma

Interventions: Drug: Carfilzomib
Other: Chemosensitivity Assay
Drug: Dexamethasone
Other: Laboratory Biomarker Analysis
Drug: Panobinostat

First Posted Date: 2017-08-21

Last Posted Date: 2022-05-09

Lead Sponsor: University of Washington

Target Recruit Count: 9

Registration Number: NCT03256045

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

Phase 3

Completed

Conditions: Relapsed Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Drug: Dexamethasone
Drug: Carfilzomib
Drug: Daratumumab

First Posted Date: 2017-05-18

Last Posted Date: 2025-05-09

Lead Sponsor: Amgen

Target Recruit Count: 466

Registration Number: NCT03158688

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Baylor Charles A Sammons Cancer Center at Dallas, Dallas, Texas, United States
🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

and more 110 locations

Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines

Phase 2

Completed

Conditions: Multiple Myeloma in Relapse

Interventions: Drug: Carfilzomib for Inj 60 milligram (MG)
Drug: Elotuzumab 400 MG
Drug: Dexamethasone

First Posted Date: 2017-05-16

Last Posted Date: 2023-09-26

Lead Sponsor: Raija Silvennoinen

Target Recruit Count: 15

Registration Number: NCT03155100

Locations: 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
🇫🇮
Central Finland Central Hospital, Jyväskylä, Finland
🇫🇮
Kymenlaakso Central Hospital, Kotka, Finland

and more 5 locations

Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients

Phase 1

Completed

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: Romidepsin
Drug: Carfilzomib

First Posted Date: 2017-05-05

Last Posted Date: 2022-05-18

Lead Sponsor: University of Birmingham

Target Recruit Count: 50

Registration Number: NCT03141203

Locations: 🇬🇧
The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
🇬🇧
Derriford Hospital, Plymouth, United Kingdom
🇬🇧
Southampton General Hospital, Southampton, United Kingdom

and more 10 locations

Combination Study for High Risk Multiple Myeloma Patients

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Pomalidomide
Drug: Carfilzomib
Drug: Dexamethasone

First Posted Date: 2017-04-07

Last Posted Date: 2022-03-31

Lead Sponsor: Oncotherapeutics

Target Recruit Count: 13

Registration Number: NCT03104270

Locations: 🇺🇸
Robert A. Moss, MD, FACP, Inc, Fountain Valley, California, United States
🇺🇸
Pacific Cancer Care, Monterey, California, United States
🇺🇸
California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States

and more 3 locations

Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Isatuximab
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2017-04-07

Last Posted Date: 2024-05-29

Lead Sponsor: Universitätsklinikum Hamburg-Eppendorf

Target Recruit Count: 246

Registration Number: NCT03104842

Locations: 🇩🇪
Vivantes Am Urban, Berlin, Germany
🇩🇪
Städt. Kliniken Bielefeld Klinikum Mitte, Bielefeld, Germany
🇩🇪
Campus Benjamin Franklin Charite Berlin, Berlin, Germany

and more 14 locations

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Phase 1

Terminated

Conditions: Plasmacytoma
Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Drug: Carfilzomib
Drug: Dexamethasone
Drug: Dexamethasone Sodium Phosphate
Procedure: Echocardiography
Drug: Lenalidomide
Drug: Navtemadlin

First Posted Date: 2017-01-26

Last Posted Date: 2024-08-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT03031730

Locations: 🇺🇸
NYP/Weill Cornell Medical Center, New York, New York, United States
🇺🇸
University of Texas at Austin, Austin, Texas, United States
🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

and more 4 locations

Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma

Phase 3

Completed

Conditions: Relapsed and Refractory Multiple Myeloma

Interventions: Drug: Dexamethasone
Drug: Carfilzomib

First Posted Date: 2017-01-24

Last Posted Date: 2022-05-25

Lead Sponsor: Amgen

Target Recruit Count: 126

Registration Number: NCT03029234

Locations: 🇨🇳
Guangzhou First Peoples Hospital, Guangzhou, Guangdong, China
🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳
West China Hospital, Sichuang University, Chengdu, Sichuan, China

and more 14 locations